Measure potential of test agents to inhibit phase I metabolizing enzymes.
Utilization of DNA adduct measurement provides clues to multiple mechanisms.
Ellagic acid and olitpraz have shown potential to study further for in vivo efficacy.
Ellagic acid demonstrated significant reduction in CYP1A2 and CYP1B1 activity and also scavenged electrophilic metabolite.
Oltipraz did not scavenge electrophilic metabolite, but inhibited CYP1A1 and CYP1B1.